PCR136 A Retrospective Analysis of Real-World Treatment Patterns in Patients over Age 64 with Dry Eye Disease Receiving OTX-101 Ophthalmic Solution 0.09%, Cyclosporine Ophthalmic Emulsion 0.05%, or Lifitegrast Ophthalmic Solution 5%

P Karpecki,V Barghout,B Schenkel,L Huynh,A Khanal,B Mitchell,M Yenikomshian,E Zanardo,C Matossian

doi:10.1016/j.jval.2023.03.1912

PCR136 A Retrospective Analysis of Real-World Treatment Patterns in Patients over Age 64 with Dry Eye Disease Receiving OTX-101 Ophthalmic Solution 0.09%, Cyclosporine Ophthalmic Emulsion 0.05%, or Lifitegrast Ophthalmic Solution 5%

P Karpecki, V Barghout + Show 7 more

https://doi.org/10.1016/j.jval.2023.03.1912

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 1, 2023
Citations: 1

Affiliation: University of Pikeville, Sun Chemical (United States), Sun Pharma (United States), Analysis Group (United States)

#Lifitegrast Ophthalmic Solution #Cyclosporine Ophthalmic Emulsion + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Dry eye disease (DED) causes chronic ocular surface inflammation and damage. DED prevalence increases with age. Cyclosporine ophthalmic solution 0.09% (CEQUA®; OTX-101), cyclosporine ophthalmic emulsion 0.05% (Restasis®; CsA), and lifitegrast ophthalmic solution 5% (Xiidra®; LFT) are anti-inflammatory agents indicated for DED treatment. We compared treatment patterns in patients >64 years with DED receiving OTX-101, CsA, or LFT.

Full Text